VIBRANTZ-TECHNOLOGIES
19.12.2023 08:46:34 CET | Business Wire | Press release
Eramet and Vibrantz Technologies today announced a 10-year agreement whereby Eramet will supply Vibrantz with manganese ore, an essential raw material used in Vibrantz’s portfolio of manganese technologies for lithium-ion battery and other applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231218880208/en/
Another significant step in both companies’ commitments to corporate social responsibility and supporting the transition to a lower emission future, the agreement builds on the 20-year Eramet-Vibrantz partnership to create a reliable pathway for Vibrantz’s manganese sulfate manufacture used in the production of electric vehicle (EV) batteries. Eramet’s manganese ore will be sourced from its Gabon mine which will undertake the Initiative for Responsible Mining Assurance’s (IRMA) audit process to align its operations with international best practices.
“This agreement confirms Eramet's ability to satisfy and win the loyalty of its customers and partners by supplying quality ore produced under responsible conditions,” said Christel Bories, Eramet Chairman and CEO. “Eramet is particularly well positioned to become a key responsible player in the battery value chain through our long-life, high-grade deposits in strategic metals, such as manganese in Gabon, lithium in Argentina at Centenario, and nickel and cobalt in Indonesia at Weda Bay.” Bories added that Eramet seeks to have all of its sites IRMA audited by 2026.
This news comes on the heels of Vibrantz’s announcement that it is constructing a pilot facility to process battery-grade high-purity manganese sulfate (HPMSM) at its Tampico, Mexico, site.
“As Vibrantz advances our commitment to becoming a sustainable and world-class specialty chemicals and materials solutions provider, we value our enduring partnership with Eramet,” said D. Michael Wilson, Vibrantz President and CEO. “This agreement allows Vibrantz to leverage both companies’ 50 years of combined expertise in manganese chemicals as we work to make environmentally friendly vehicles a growing reality for millions of consumers.” Wilson also said the company continues to receive positive market reception of its recent HPMSM capacity investments from battery producers and automotive original equipment manufacturers.
Explore Eramet’s activities here and learn more about Vibrantz’s trusted manganese technologies utilized in battery, agriculture, construction, electronics and water treatment end-use markets.
About Eramet
Eramet transforms the Earth’s mineral resources to provide sustainable and responsible solutions to the growth of the industry and to the challenges of the energy transition. Its employees are committed to this through their civic and contributory approach in all the countries where the mining and metallurgical group is present. Eramet recovers and develops metals essential to the construction of a more sustainable world. Fully committed to the era of metals, Eramet’s ambition is to become a reference for the responsible transformation of the Earth’s mineral resources for living well together.
Visit www.eramet.com.
About Vibrantz Technologies
Vibrantz is a leading global provider of specialty chemicals and materials whose purpose is to bring color, performance and vibrancy to life. Serving over 11,000 customers, our products and technologies serve a wide array of applications and make their way into myriad consumer products. With key competencies in particle engineering, glass and ceramic science and color technology, Vibrantz has leading positions in specialty mineral and chemical additives for batteries, electronic components and construction; pigments for paints and coatings, thermoset plastics and thermoplastics; and high-performance glass coatings and porcelain enamel solutions. Headquartered in Houston, Texas, the company employs approximately 5,000 people and operates 65 manufacturing sites across six continents.
Visit vibrantz.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231218880208/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
